Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC receives funding grant for IMHA research
Dogs with IMHA present with pale pink mucous membranes.

IMHA is a serious and often fatal blood disease of dogs.

The Royal Veterinary College has received more than $99,000 of funding to advance research into immune-mediated haemolytic anaemia (IMHA).

The grant from Allen and Barbara Dearry, through the Morris Animal Foundation, aims to support the study of mechanisms that cause IMHA using state-of-the-art single-cell RNA sequencing techniques. Furthermore, it will support the evaluation of various treatments with fewer side effects.

IMHA is a serious and often fatal blood disease of dogs that occurs when the immune system starts attacking its own red blood cells, eventually leading to their destruction. 

It is usually treated with medications that suppress the immune system and prevent the body from destroying its own red blood cells. However, these medications also cause serious side effects, such as panting, muscle wastage and lethargy, which can be distressing for dogs and their owners. 

The research, led by Dr Barbara Glanemann, associate professor in small animal medicine at the RVC, will use new technology to assess each blood cell collected from dogs with IMHA. The findings will enhance understanding of gene activation, and shed light on the underlying issues within the patient's immune system.

Researchers will compare the results to those from healthy dogs to learn how and why the immune attacks red blood cells and could find new therapeutic targets for drug development. 

Furthermore, the team will assess how cells from dogs with IMHA respond to common medications to create prediction models that vets can use to help decide which medication would be most appropriate. 

Dr Barbara Glanemann said: “We are excited to uncover new information on how IMHA develops in our dogs and are hoping to identify what therapy works best for individual dogs, which could have a major impact on the quality of life for dogs with this distressing disease.”

Dr Kelly Diehl, senior director of science ommunications at Morris Animal Foundation, added: "We’re very excited to fund these projects and we hope to make a significant difference in the understanding and treatment of this important but underfunded disease.”

Image (C) RVC.
 

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.